tarcocimab tedromer
Generic: KSI-301·Code: KSI-301
tarcocimab tedromer: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Kodiak Sciences Inc. (KOD) | Phase 3 |
Clinical Trials (1)
A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Three-arm Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tarcocimab Tedromer and Tabirafusp Tedromer Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
Frequently asked questions
Who is developing tarcocimab tedromer?
tarcocimab tedromer is being developed by Kodiak Sciences Inc..
How many clinical trials involve tarcocimab tedromer?
BioSniper tracks 1 clinical trial involving tarcocimab tedromer.
Get deeper analysis on tarcocimab tedromer
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis